Thrombosis - Pipeline Review, H2 2014

Publisher Name :
Date: 31-Dec-2014
No. of pages: 156
Inquire Before Buying

Global Markets Direct's, ‘Thrombosis Pipeline Review, H2 2014', provides an overview of the Thrombosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Thrombosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope


  • The report provides a snapshot of the global therapeutic landscape of Thrombosis

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in the therapeutics development for Thrombosis and enlists all their major and minor projects

  • The report summarizes all the dormant and discontinued pipeline projects

  • A review of the Thrombosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • A detailed assessment of monotherapy and combination therapy pipeline projects

  • Coverage of the Thrombosis pipeline on the basis of target, MoA, route of administration and molecule type

  • Latest news and deals relating related to pipeline products


Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Identify and understand important and diverse types of therapeutics under development for Thrombosis

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Devise corrective measures for pipeline projects by understanding Thrombosis pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Thrombosis - Pipeline Review, H2 2014

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Thrombosis Overview 8
Therapeutics Development 9
Pipeline Products for Thrombosis - Overview 9
Pipeline Products for Thrombosis - Comparative Analysis 10
Thrombosis - Therapeutics under Development by Companies 11
Thrombosis - Therapeutics under Investigation by Universities/Institutes 14
Thrombosis - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Thrombosis - Products under Development by Companies 21
Thrombosis - Products under Investigation by Universities/Institutes 24
Thrombosis - Companies Involved in Therapeutics Development 26
Archemix Corp. 26
Astellas Pharma Inc. 27
AstraZeneca PLC 28
Bristol-Myers Squibb Company 29
Cardax Pharmaceuticals, Inc. 30
CSL Limited 31
Daewoong Pharmaceutical Co., Ltd. 32
IMMD Inc. 33
Isis Pharmaceuticals, Inc. 34
LG Life Sciences, Ltd. 35
Lipicard Technologies Limited 36
Medicure Inc. 37
Merck & Co., Inc. 38
MSM Protein Technologies, Inc. 39
Nostrum Pharmaceuticals, LLC 40
Pfizer Inc. 41
PLx Pharma Inc. 42
Portola Pharmaceuticals, Inc. 43
Sagene Pharmaceuticals, Inc. 44
SciFluor Life Sciences, LLC 45
Zedira GmbH 46
Thrombosis - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Target 49
Assessment by Mechanism of Action 52
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 58
ANV-6L15 - Drug Profile 58
ARC-15105 - Drug Profile 59
ASP-6537 - Drug Profile 60
aspirin - Drug Profile 62
BMS-262084 - Drug Profile 64
BMS-816106 - Drug Profile 65
BMS-884775 - Drug Profile 66
CDX-085 - Drug Profile 67
CLB-100 - Drug Profile 69
CSL-3F7 - Drug Profile 70
DD-2 - Drug Profile 71
Drug for Thrombosis - Drug Profile 72
Drug to Activate Endothelial Protein C Receptor for Inflammation and Thrombosis - Drug Profile 73
Drugs for Thrombosis - Drug Profile 74
DWJ-1261 - Drug Profile 75
DWJ-1355 - Drug Profile 76
IMD-4852 - Drug Profile 77
Ir-CPI - Drug Profile 78
ISIS-FVIIRx - Drug Profile 79
LC-231306 - Drug Profile 80
LT-5121 - Drug Profile 81
LT-5122 - Drug Profile 82
LT-5521 - Drug Profile 83
MC-45301 - Drug Profile 84
MC-45308 - Drug Profile 85
MC-45350 - Drug Profile 86
MC-45403 - Drug Profile 87
Monoclonal Antibodes to Activate TREM-like transcript-1 Receptor for Thrombosis and Hemostasis - Drug Profile 88
MSM-236 - Drug Profile 89
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 90
Peptides for Immunology and Cardiovascular Disorders - Drug Profile 91
PF-00190434 - Drug Profile 92
PRT-060318 - Drug Profile 93
Recombinant Protein for Thrombosis and Non-Small Cell Lung Cancer - Drug Profile 94
Recombinant Protein for Thrombosis and Stroke - Drug Profile 95
Recombinant Proteins to Inhibit Serine Protease for Thrombosis, Ischemic Stroke and Atherosclerosis - Drug Profile 96
rGPG-290 - Drug Profile 97
S-002333 - Drug Profile 98
S-007867 - Drug Profile 99
selegiline + Antiplatelet Drugs - Drug Profile 100
Small Molecule for Thrombosis - Drug Profile 101
Small Molecule for Thrombosis - Drug Profile 102
Small Molecule to Antagonize P2Y12 for Thrombosis - Drug Profile 103
Small Molecule to Inhibit ASK1 for Thrombosis - Drug Profile 104
Small Molecule to Inhibit Factor XIa for Thrombosis - Drug Profile 105
Small Molecule To inhibit PAR-1 for Atherothrombosis - Drug Profile 106
Small Molecules for Hematological Disorders and Cancer - Drug Profile 107
Small Molecules for Thrombosis - Drug Profile 108
Small Molecules for Thrombosis and Stroke - Drug Profile 109
Small Molecules to Inhibit Carboxypeptidase U for Thrombosis - Drug Profile 110
Small Molecules to Inhibit Factor XIII for Thrombosis - Drug Profile 111
Small Molecules to Inhibit P2Y12 Receptor for Thrombosis - Drug Profile 112
Small Molecules to Inhibit PDI for Thrombosis - Drug Profile 113
Small Molecules to Inhibit Purinergic Receptor for Thrombosis - Drug Profile 114
Small Molecules to Inhibit Thrombin for Thrombosis and Oncology - Drug Profile 115
Small Molecules to Inhibit TNF-a for Cardiovascular and CNS Disorders - Drug Profile 116
SMRX-11 - Drug Profile 117
Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury - Drug Profile 118
Synthetic Peptides to Inhibit Glycoprotein VI for Thrombosis - Drug Profile 119
Tanshinone IIA - Drug Profile 120
TM-5275 - Drug Profile 121
TM-5509 - Drug Profile 122
TTS-01 - Drug Profile 123
UM-8190 - Drug Profile 124
vorapaxar sulfate - Drug Profile 125
Thrombosis - Recent Pipeline Updates 127
Thrombosis - Dormant Projects 130
Thrombosis - Discontinued Products 135
Thrombosis - Product Development Milestones 137
Featured News & Press Releases 137
Appendix 150
Methodology 150
Coverage 150
Secondary Research 150
Primary Research 150
Expert Panel Validation 150
Contact Us 151
Disclaimer 151

List of Tables

Number of Products under Development for Thrombosis, H2 2014 14
Number of Products under Development for Thrombosis - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 17
Number of Products under Development by Companies, H2 2014 (Contd..1) 18
Number of Products under Investigation by Universities/Institutes, H2 2014 20
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 21
Comparative Analysis by Late Stage Development, H2 2014 22
Comparative Analysis by Clinical Stage Development, H2 2014 23
Comparative Analysis by Early Stage Development, H2 2014 24
Comparative Analysis by Unknown Stage Development, H2 2014 25
Products under Development by Companies, H2 2014 26
Products under Development by Companies, H2 2014 (Contd..1) 27
Products under Development by Companies, H2 2014 (Contd..2) 28
Products under Investigation by Universities/Institutes, H2 2014 29
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 30
Thrombosis - Pipeline by Archemix Corp., H2 2014 31
Thrombosis - Pipeline by Astellas Pharma Inc., H2 2014 32
Thrombosis - Pipeline by AstraZeneca PLC, H2 2014 33
Thrombosis - Pipeline by Bristol-Myers Squibb Company, H2 2014 34
Thrombosis - Pipeline by Cardax Pharmaceuticals, Inc., H2 2014 35
Thrombosis - Pipeline by CSL Limited, H2 2014 36
Thrombosis - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2014 37
Thrombosis - Pipeline by IMMD Inc., H2 2014 38
Thrombosis - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 39
Thrombosis - Pipeline by LG Life Sciences, Ltd., H2 2014 40
Thrombosis - Pipeline by Lipicard Technologies Limited, H2 2014 41
Thrombosis - Pipeline by Medicure Inc., H2 2014 42
Thrombosis - Pipeline by Merck & Co., Inc., H2 2014 43
Thrombosis - Pipeline by MSM Protein Technologies, Inc., H2 2014 44
Thrombosis - Pipeline by Nostrum Pharmaceuticals, LLC, H2 2014 45
Thrombosis - Pipeline by Pfizer Inc., H2 2014 46
Thrombosis - Pipeline by PLx Pharma Inc., H2 2014 47
Thrombosis - Pipeline by Portola Pharmaceuticals, Inc., H2 2014 48
Thrombosis - Pipeline by Sagene Pharmaceuticals, Inc., H2 2014 49
Thrombosis - Pipeline by SciFluor Life Sciences, LLC, H2 2014 50
Thrombosis - Pipeline by Zedira GmbH, H2 2014 51
Assessment by Monotherapy Products, H2 2014 52
Assessment by Combination Products, H2 2014 53
Number of Products by Stage and Target, H2 2014 55
Number of Products by Stage and Mechanism of Action, H2 2014 58
Number of Products by Stage and Route of Administration, H2 2014 60
Number of Products by Stage and Molecule Type, H2 2014 62
Thrombosis Therapeutics - Recent Pipeline Updates, H2 2014 132
Thrombosis - Dormant Projects, H2 2014 135
Thrombosis - Dormant Projects (Contd..1), H2 2014 136
Thrombosis - Dormant Projects (Contd..2), H2 2014 137
Thrombosis - Dormant Projects (Contd..3), H2 2014 138
Thrombosis - Dormant Projects (Contd..4), H2 2014 139
Thrombosis - Discontinued Products, H2 2014 140
Thrombosis - Discontinued Products (Contd..1), H2 2014 141

List of Figures

Number of Products under Development for Thrombosis, H2 2014 14
Number of Products under Development for Thrombosis - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 16
Number of Products under Investigation by Universities/Institutes, H2 2014 19
Comparative Analysis by Late Stage Development, H2 2014 22
Comparative Analysis by Clinical Stage Development, H2 2014 23
Comparative Analysis by Early Stage Products, H2 2014 24
Assessment by Monotherapy Products, H2 2014 52
Number of Products by Top 10 Targets, H2 2014 54
Number of Products by Stage and Top 10 Targets, H2 2014 54
Number of Products by Top 10 Mechanism of Actions, H2 2014 57
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 57
Number of Products by Top 10 Routes of Administration, H2 2014 59
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 59
Number of Products by Top 10 Molecule Types, H2 2014 61
Number of Products by Stage and Top 10 Molecule Types, H2 2014 61

  • Healthy Diet Demand In Developed Economies To Boost Nutraceuticals
    As customers scuffle to keep up with the frantic lifestyles, the necessity for healthy nutrition rises owing to dearth of time to spend on laborious exercises.  Customers are shifting their attention to swift and healthy food behaviours. Increase in intake of beverages and functional food has offered makers of nutraceuticals with money-spinning prospects to benefit [...]
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • Siemens Adds To the Growth of Wind Power Generation Market
    Siemens has been presenting ground-breaking strategies and pioneering solutions for energy generation for an intelligent power supply globally. With an expansive portfolio and wide-ranging proficiency in wind power generation, Siemens is likely to aid in increasing the share of wind power in the US energy mix. With New Mexico’s vicinity to significant wind energy areas, [...]
  • Global Public Safety LTE Ecosystem Overview
    In view of its flourishing ecosystem, spectrum flexibility and performance metrics, LTE has emerged as the leading candidate for public safety mobile broadband networks. Public safety organizations and establishments have already begun planning to advance their networks to LTE-based public safety solutions. LTE provisions a varied range of services, from high bandwidth data services to [...]
  • RnR Market Research: Biochips Market Insights
    Growing R&D investment and subcontracting of pharmaceutical companies would lead to growth in biochips market in Asia along with an increase in the application of biochips products is estimated to improve opportunity for the global biochip market. Conversely, the high cost involved in manufacturing of biochips can be seen as a challenge for the same. [...]
  • Deep Vein Thrombosis (DVT)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Deep Vein Thrombosis (DVT)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Deep Vein Thrombosis (DVT) Report is to understand the market and pipeline status of the drugs around the Deep Vein Thrombosis (DVT) to explore the generic development oppo......
  • Essential Thrombocythemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Essential Thrombocythemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Essential Thrombocythemia Report is to understand the market and pipeline status of the drugs around the Essential Thrombocythemia to explore the generic development opportu......
  • Bacteremia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Bacteremia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Bacteremia Report is to understand the market and pipeline status of the drugs around the Bacteremia to explore the generic development opportunities, licensing opportunities and to gain c......
  • Hemophilia A-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Hemophilia A-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hemophilia A Report is to understand the market and pipeline status of the drugs around the Hemophilia A to explore the generic development opportunities, licensing opportunities and to ......
  • Hemophilia B-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Hemophilia B-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hemophilia B Report is to understand the market and pipeline status of the drugs around the Hemophilia B to explore the generic development opportunities, licensing opportunities and to ......
  • Hereditary Angioedema (HAE)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Hereditary Angioedema (HAE)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hereditary Angioedema (HAE) Report is to understand the market and pipeline status of the drugs around the Hereditary Angioedema (HAE) to explore the generic development o......
  • Hyperuricemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Hyperuricemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hyperuricemia Report is to understand the market and pipeline status of the drugs around the Hyperuricemia to explore the generic development opportunities, licensing opportunities and ......
  • Hypocalcemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Hypocalcemia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hypocalcemia Report is to understand the market and pipeline status of the drugs around the Hypocalcemia to explore the generic development opportunities, licensing opportunities and to ......
  • Hyponatremia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016
    Published: 01-Sep-2016        Price: US 2000 Onwards        Pages: 100
    Summary DelveInsight's Report, "Hyponatremia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016", provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturers across the globe. A key objective of the Hyponatremia Report is to understand the market and pipeline status of the drugs around the Hyponatremia to explore the generic development opportunities, licensing opportunities and to ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs